Simplex Trading, LLC Aeglea Bio Therapeutics, Inc. Transaction History

Simplex Trading, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 04, 2023	BUY	$0.11 - $0.46 $301 - $1,262	2,744 Added 4900.0%	2,800 $1,000
Q4 2022 Feb 02, 2023	SELL	$0.35 - $1.54 $4,572 - $20,120	-13,065 Reduced 99.57%	56 $0
Q3 2022 Nov 04, 2022	BUY	$0.38 - $0.81 $4,981 - $10,617	13,108 Added 100830.77%	13,121 $6,000
Q2 2022 Aug 03, 2022	BUY	$0.5 - $2.66 $6 - $34	13 New	13 $0
Q1 2021 Apr 26, 2021	SELL	$6.76 - $8.57 $858 - $1,088	-127 Closed	0 $0
Q4 2020 Feb 02, 2021	BUY	$7.02 - $9.83 $449 - $629	64 Added 101.59%	127 $0
Q3 2020 Oct 14, 2020	SELL	$6.51 - $9.33 $4,511 - $6,465	-693 Reduced 91.67%	63 $0
Q2 2020 Jul 13, 2020	BUY	$4.01 - $11.04 $2,919 - $8,037	728 Added 2600.0%	756 $6,000
Q1 2020 Apr 29, 2020	SELL	$3.51 - $8.48 $2,446 - $5,910	-697 Reduced 96.14%	28 $0
Q4 2019 Feb 05, 2020	SELL	$7.23 - $8.55 $4,207 - $4,976	-582 Reduced 44.53%	725 $5,000
Q3 2019 Oct 15, 2019	SELL	$6.42 - $9.0 $5,277 - $7,398	-822 Reduced 38.61%	1,307 $10,000
Q2 2019 Jul 26, 2019	BUY	$6.1 - $8.78 $12,986 - $18,692	2,129 New	2,129 $14,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Simplex Trading, LLC with notifications on news.